Esperion Therapeutics, Inc. (ESPR): Timothy M Mayleben , CEO of Esperion Therapeutics, Inc. purchased 7,000 shares on May 4, 2016. The Insider buying transaction was reported by the company on May 5, 2016 to the Securities and Exchange Commission. The shares were purchased at $14.85 per share for a total value of $103,950.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 2, 2016, Gilbert S Omenn (director) purchased 5,000 shares at $15.28 per share price.On Jan 28, 2016, Timothy M Mayleben (CEO) purchased 3,600 shares at $15.88 per share price.Also, On Apr 27, 2015, Dov A Md Goldstein (director) sold 217,469 shares at $107.73 per share price.On Mar 23, 2015, Patrick G Enright (director) sold 500,000 shares at $113.04 per share price.
Shares of Esperion Therapeutics Inc (ESPR) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -1.2 points or -7.71% at $14.37 with 12,52,286 shares getting traded. Post opening the session at $15.35, the shares hit an intraday low of $13.5 and an intraday high of $15.44 and the price vacillated in this range throughout the day. The company has a market cap of $324 M and the number of outstanding shares has been calculated to be 2,25,40,466 shares. The 52-week high of Esperion Therapeutics Inc is $120.96 and the 52-week low is $12.61.
Company has been under the radar of several Street Analysts.Esperion Therapeutics Inc is Reiterated by Chardan Capital Markets to Neutral while Lowering the Price Target of the company shares to $ 13 from a previous price target of $18 . The Rating was issued on Feb 26, 2016.Esperion Therapeutics Inc is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 64 from a previous price target of $105 . The Rating was issued on Feb 25, 2016.
Esperion Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Company’s primary activities include conducting research and development activities including nonclinical preclinical and clinical testing performing business and financial planning recruiting personnel and raising capital. ETC-1002 the Company’s lead product candidate is an orally available once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.